Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

@inproceedings{Cortes2017Phase1D,
  title={Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia},
  author={Jorge E. Cortes and Moshe Talpaz and Hedy P. Smith and D. Stephen Snyder and Jean Khoury and Kapil N. Bhalla and Javier Pinilla-Ibarz and Richard A Larson and David Y. Mitchell and Scott C. Wise and Thomas J. Rutkoski and B. Douglas Smith and Daniel L. Flynn and Hagop M Kantarjian and Oliver Rosen and Richard A. Van Etten},
  booktitle={Haematologica},
  year={2017}
}
A vailable tyrosine kinase inhibitors for chronic myeloid leukemia bind in an adenosine 5'-triphosphate-binding pocket and are affected by evolving mutations that confer resistance. Rebastinib was identified as a switch control inhibitor of BCR-ABL1 and FLT3 and may be active against resistant mutations. A Phase 1, first-in-human, single-agent study investigated rebastinib in relapsed or refractory chronic or acute myeloid leukemia. The primary objectives were to investigate the safety of… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Ocular toxicities of MEK inhibitors and other targeted therapies.

Annals of oncology : official journal of the European Society for Medical Oncology • 2016

Final results of a randomized phase 2 study showing the clinical benefit of quizartinib ( AC 220 ) in patients with FLT 3 - ITD positive relapsed or refractory acute myeloid leukemia

GJ Schiller, MS Tallman, SL Goldberg
J Clin Oncol • 2014

TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2013

Similar Papers

Loading similar papers…